There are 2789 resources available
933P - Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
Presenter: Jean-Luc van Laethem
Session: ePoster Display
934P - The TARGET study: A global investigation of advanced dosimetry for transarterial radioembolization of hepatocellular carcinoma with yttrium-90 glass microspheres
Presenter: Marnix Lam
Session: ePoster Display
935P - An exploratory subgroup analysis of a phase II/III trial of donafenib versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma
Presenter: Feng Bi
Session: ePoster Display
936P - Effects of tislelizumab (TIS) monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma (HCC)
Presenter: Zhenggang Ren
Session: ePoster Display
913P - Apatinib for heavily pretreated recurrent and/or metastatic head and neck squamous cell carcinoma: Updated analysis
Presenter: kunyu yang
Session: ePoster Display
914P - Impact of induction chemotherapy (ICT) in borderline resectable or unresectable locally advanced oral squamous cell carcinoma (OSCC)
Presenter: Divya Kukreja
Session: ePoster Display
1022P - Frequency of PD1-negative and PD-1-positive ILCs in breast cancer patients depending on PD-L1 status
Presenter: Vladimir Alifanov
Session: ePoster Display
1023P - A novel microbiome-derived peptide, SG-3-00802 reverses resistance to anti-programmed death protein-1 (PD-1) therapy
Presenter: Helena Kiefel
Session: ePoster Display
1025TiP - SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI)
Presenter: Aleix Prat
Session: ePoster Display